rs3024491 — IL10 Intronic variant

IL-10 Intronic Variant — A Hidden Dial on Your Anti-Inflammatory Thermostat

Interleukin-10 (IL-10) is the immune system's master brake pedal. Without adequate IL-10, the body's inflammatory responses run longer and harder than necessary — a pattern that underlies conditions ranging from inflammatory bowel disease to asthma to susceptibility to bacterial infections. rs3024491 sits in intron 2 of the IL10 gene¹¹ intron 2 of the IL10 gene
A non-coding region within the gene's second intron, located at chromosome 1q32.1, and functions as an independent regulatory switch distinct from the well-studied promoter haplotypes (rs1800896, rs1800871, rs1800872). IL10 is encoded on the minus (reverse) strand, so while genome files report the plus-strand C and A alleles, the published literature often describes the complementary G and T alleles — the A allele here corresponds to what many papers call the T allele.

The Mechanism

Because rs3024491 lies within an intron rather than the coding sequence, it does not change the IL-10 protein structure. Instead, it influences how much IL-10 gets produced. Intronic variants can affect gene expression through several mechanisms²² gene expression through several mechanisms
Including altered splicing efficiency, disruption of intronic enhancer elements, and changes to RNA secondary structure that affect transcript stability. The A allele (coding-strand T) reduces IL-10 output, while the common C allele maintains normal production. This regulatory effect is independent of the promoter haplotype system — meaning someone with a "normal" promoter can still carry the intronic A allele and produce less IL-10 than expected.

The functional consequence is a shift in immune tone. Lower IL-10 means the immune system is slower to call off its inflammatory response after infection or tissue injury. In the gut, this creates conditions where the mucosal immune system is more reactive to the normal commensal bacteria — a central feature of inflammatory bowel disease. In the airway, it means allergen-triggered inflammation resolves more slowly. In the stomach, it may allow H. pylori³³ H. pylori
A bacteria that colonizes ~50% of people globally, causing gastric inflammation and long-term risk of gastric ulcer and cancer to establish infection more easily, partly because the bug itself exploits IL-10 to dampen host defenses.

The Evidence

The strongest functional data comes from a Brazilian pediatric study examining 123 asthmatic children and 58 controls⁴⁴ examining 123 asthmatic children and 58 controls
Assis et al. 2021, Association between interleukin-10 polymorphisms and CD4+CD25+FOXP3+ T cells in asthmatic children, published in the Journal of Investigational Allergology and Clinical Immunology. The AA genotype (TT in coding-strand notation) was associated with significantly reduced IL-10 serum levels (p = 0.01) and a higher frequency of regulatory T cells (p = 0.01). The A allele appeared more often in children with moderate asthma compared to mild asthma or controls (71.4% vs. 48.5%, p = 0.042), identifying rs3024491 as the most consistently significant of the four IL-10 polymorphisms studied.

A Brazilian birth-cohort study of 1,259 children aged 4–11 years⁵⁵ aged 4–11 years
Assis et al. 2014, IL10 SNPs related to upregulation of constitutive IL-10 production and H. pylori susceptibility, published in Helicobacter found that carriers of the A allele had significantly increased susceptibility to H. pylori infection (OR = 1.71; 95% CI 1.14–2.57, p = 0.01), associated with higher constitutive IL-10 production in culture — a counterintuitive finding suggesting the variant may modulate infection-triggered immune suppression rather than simply lowering baseline IL-10 uniformly.

A Tunisian study on cervical cancer susceptibility⁶⁶ cervical cancer susceptibility
Barbouche et al. 2015, IL-10 gene promoter and intron polymorphisms as genetic biomarkers, published in Cytokine confirmed that the minor allele of rs3024491 was associated with reduced IL-10 secretion, consistent with the mechanistic picture of the A allele as a low-producer variant.

At the locus level, the IL10 region on chromosome 1q32 is one of the most robustly replicated IBD susceptibility loci in GWAS, achieving p = 1.35 × 10⁻¹² for ulcerative colitis in the landmark 2008 Nature Genetics study. The lead GWAS SNP (rs3024505, ~5 kb downstream of IL10) is in linkage disequilibrium with intronic variants including rs3024491, and conditional analyses suggest multiple independent signals across the locus. rs3024491's independently documented effect on IL-10 output makes it a biologically plausible contributor to this susceptibility architecture.

Practical Actions

The A allele's reduced IL-10 output creates a more pro-inflammatory baseline that is particularly relevant for gut health and respiratory inflammation. Anti-inflammatory dietary strategies can partially compensate: omega-3 fatty acids (EPA/DHA) have documented IL-10-upregulating effects, curcumin activates IL-10 transcription via NF-κB modulation, and vitamin D supports IL-10 production in regulatory T cells. For anyone with AA genotype who develops gastrointestinal symptoms, early evaluation for inflammatory bowel disease is warranted — the diagnostic delay for IBD averages years, and genetic awareness can prompt earlier investigation.

H. pylori infection is worth testing for in A allele carriers, especially those with dyspepsia or a family history of gastric disease, as eradication therapy eliminates a major chronic inflammatory stimulus that low IL-10 producers handle less efficiently.

Interactions

rs3024491 operates as an independent layer of IL-10 regulation on top of the promoter haplotype system defined by rs1800896, rs1800871, and rs1800872. Carriers of both the intronic A allele at rs3024491 and the low-producing promoter haplotype (ATA, defined by the A allele at rs1800896) face compound reduction in IL-10 transcription from two distinct regulatory elements. This stacked low-producer state is likely to show stronger effects on IBD susceptibility and inflammatory disease severity than either variant alone — though direct compound studies are limited. The two regulatory systems should be considered together when assessing overall IL-10 production capacity.